In 2023, antihypertensive medicine sales in Türkiye stood at 12.8 million US dollars. The forecasted data from 2024 to 2028 shows a slight downward trend. Sales are projected to decline marginally from 12.7 million US dollars in 2024 to 12.5 million US dollars by 2028.
Year-on-year analysis reveals minor variations:
- From 2023 to 2024: -0.78%
- From 2024 to 2025: -0.79%
- From 2025 to 2026: -0.79%
The Compound Annual Growth Rate (CAGR) over the last five years is approximately -0.47%, indicating a consistent but slight decline in sales of antihypertensive medicines in the market.
Future trends to watch for include the impact of new, more effective antihypertensive treatments entering the market, potential healthcare policy changes, and the overall economic conditions in Türkiye, which may influence healthcare spending and drug affordability.
